Company-wide revenue
Reported revenue in 2021 ¥559M Reported revenue in 2025 ¥429M
- growth amount
- −¥130M
- growth annualized
- -6.4%
- growth total
- -23.3%
Japanese company profile · 4597
The original Japanese company name is shown; no English name has been verified.
FY2025 · fiscal year ended December 2025Latest filing date: 2026-03-24What does this company do?
The latest available public filing reports Development and Sales of Pharmaceuticals and Related Products. The original Japanese company name is shown with the source information.
This company's largest reported business by revenue in FY2025 was Development and Sales of Pharmaceuticals and Related Products.
FY2025 · fiscal year ended December 2025 · View original filing ↗ The source document may be in Japanese.
IFRS · Consolidated company-wide
Public information is organized and presented by P16. EDINET filer list (2026-11-07) Opens in a new tab · EDINET PDL 1.0 terms Opens in a new tab
Business structure
| Business | Segment revenue | Share of company sales | Segment profit (loss) | Margin |
|---|---|---|---|---|
| Development and Sales of Pharmaceuticals and Related Products | ¥429M ↗ | — | −¥861M ↗ | -200.7% |
All values are in Japanese yen (JPY). No currency conversion is applied. FY2025 · fiscal year ended December 2025. Revenue and profit are shown only where the filing and data support a comparison. “—” means a comparable amount was not disclosed. We compare sales to outside customers for each business and the company as a whole, using the same filing, fiscal year and scope. Reported business sales may include sales between businesses. We leave the share blank when the figures cannot be matched.
Company revenue
Only reported years are shown. Missing years are left blank; accounting standards and scopes are kept in separate series.
Reported Segment revenue by business over time
| Fiscal year | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Development and Sales of Pharmaceuticals and Related Products | ¥559M | ¥1.09B | ¥617M | ¥316M | ¥429M |
All amounts are in Japanese yen (JPY). Each figure links to the original Japanese filing. Blank cells indicate no comparable figure was disclosed. Business figures may not add up to consolidated figures.
What is growing?
Reported revenue in 2021 ¥559M Reported revenue in 2025 ¥429M
This describes a reported period; it is not a forecast.
What has changed?
A five-year business-mix comparison is not shown because the available filings do not provide five comparable years on the same basis.
Source
These scores summarize company characteristics using public filings. Comparison groups vary by measure. Higher is not always better.
Source
FY2025 · fiscal year ended December 2025
The source document may be in Japanese.
Filing ID: S100XT68
View original filing ↗